江河集團(601886.SH)全資子公司向EAB授予期權暨擬轉讓Healius股份
格隆匯2月25日丨江河集團(601886.SH)公佈,公司通過全資子公司持有澳大利亞上市公司Healius合計9894.67萬股股份,為其第一大股東。公司全資子公司Jangho Health Care Australia Pty Ltd(下稱“Jangho”)、Golden Acumen Holdings Limited (下稱“Golden Acumen”)與EAB Holdings Pte. Ltd.(下稱“EAB”或“期權持有人”)簽署了認購期權契約(下稱“期權契約”),約定以澳幣3000.002萬元期權費向EAB授予一項期權,EAB可在期權期內任何時間就公司持有Healius的全部9894.67萬股股份以每股澳幣3.3元行權價進行行權,行權後EAB將持有上述股份。
Healius成立於1994年,總部位於澳大利亞悉尼,於1998年7月3日在澳大利亞證券交易所發行上市,主營業務為醫療中心、第三方病理檢驗、第三方影像檢驗等。
公司堅持建築裝飾板塊和醫療健康板塊“雙主業”的發展戰略,公司參股持有Healius約15.9%股份為公司醫療板塊的一部分,並將其指定為按照公允價值計量且其變動計入其他綜合收益的金融資產進行財務核算。針對Healius併購,公司始終保持謹慎態度,如收購Healius有助於公司利益,公司方會進一步推進,否則公司亦可終止收購。本次針對參股的Healius股份簽署期權契約並不會改變公司發展醫療健康板塊業務的既定戰略。公司在保持建築裝飾板塊業務穩健發展的同時,繼續大力發展醫療健康板塊業務。
如期權持有人或其關聯實體收購標的公司簽署的收購協議生效或期權持有人(或其指定人)行權交割完成,公司可獲得澳幣3000.002萬元期權費及至少包括澳幣3.27億元行權價款合計澳幣3.57億元的現金流入,摺合人民幣約16.7億元。如期權持有人或其關聯實體成功收購標的公司並且簽署的生效收購協議中約定的每股協議價高於行權價,則期權持有人或其指定人將每股協議價與行權價的價差對應的期權股份價款支付給公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.